KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Acadia Pharmaceuticals (ACAD) EBT (2016 - 2025)

Historic EBT for Acadia Pharmaceuticals (ACAD) over the last 17 years, with Q3 2025 value amounting to $44.6 million.

  • Acadia Pharmaceuticals' EBT rose 1493.07% to $44.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $273.7 million, marking a year-over-year increase of 10019.31%. This contributed to the annual value of $258.1 million for FY2024, which is 60567.25% up from last year.
  • Acadia Pharmaceuticals' EBT amounted to $44.6 million in Q3 2025, which was up 1493.07% from $40.2 million recorded in Q2 2025.
  • Over the past 5 years, Acadia Pharmaceuticals' EBT peaked at $161.1 million during Q4 2024, and registered a low of -$112.6 million during Q1 2022.
  • Moreover, its 5-year median value for EBT was -$14.8 million (2021), whereas its average is -$3.2 million.
  • Per our database at Business Quant, Acadia Pharmaceuticals' EBT crashed by 9739.92% in 2023 and then soared by 48647.33% in 2024.
  • Quarter analysis of 5 years shows Acadia Pharmaceuticals' EBT stood at -$42.9 million in 2021, then grew by 4.8% to -$40.8 million in 2022, then skyrocketed by 197.21% to $39.7 million in 2023, then surged by 305.7% to $161.1 million in 2024, then crashed by 72.31% to $44.6 million in 2025.
  • Its EBT was $44.6 million in Q3 2025, compared to $40.2 million in Q2 2025 and $27.8 million in Q1 2025.